Eupraxia Pharmaceuticals's total assets for Q2 2026 were C$139.68M, a decrease of -3.97% from the previous quarter. EPRX total liabilities were C$10.22M for the fiscal quarter, a 11.39% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.